Longitudinal Microperimetric Changes of Macular Sensitivity in Stargardt Disease After 12 Months: ProgStar Report No. 13.

ABSTRACT:

Importance

Functional end points for clinical trials investigating the efficacy of emerging treatments for Stargardt disease type 1 (STGD1) are needed.

Objective

To assess the yearly rate of change of macular function in patients with STGD1 using microperimetry.

Design, setting, and participants

This multicenter prospective cohort study was conducted in an international selection of tertiary referral centers from October 21, 2013, to February 15, 2017. The study included participants with ABCA4-related STGD1 who were enrolled in the Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) study at baseline. Data were analyzed from February 16, 2017, to December 1, 2019.

Exposure

ABCA4-related STGD1 with a minimum lesion size on fu

SUBMITTER: Schonbach EM 

PROVIDER: S-EPMC7256863 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature